Is Oramed Pharmaceuticals Stock a Good Investment?
Oramed Pharmaceuticals Investment Advice | ORMP |
- Examine Oramed Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Oramed Pharmaceuticals' leadership team and their track record. Good management can help Oramed Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Oramed Pharmaceuticals' business and its evolving consumer preferences.
- Compare Oramed Pharmaceuticals' performance and market position to its competitors. Analyze how Oramed Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Oramed Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Oramed Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Oramed Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Oramed Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Oramed Pharmaceuticals Stock
Researching Oramed Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oramed Pharmaceuticals had not issued any dividends in recent years. The entity had 1:12 split on the 23rd of January 2013.
To determine if Oramed Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oramed Pharmaceuticals' research are outlined below:
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (10.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Oramed Pharmaceuticals Share Price Passes Below 200-Day Moving Average - Should You Sell - MarketBeat |
Oramed Pharmaceuticals Quarterly Accounts Payable |
|
Oramed Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oramed Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oramed Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Oramed Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Oramed Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | 0.02 | 0.04 | 0.02 | 100 | ||
2024-05-09 | 2024-02-29 | 0.02 | 0.04 | 0.02 | 100 | ||
2016-01-13 | 2015-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2016-01-13 | 2015-11-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2014-01-14 | 2013-12-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2014-01-14 | 2013-11-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2024-08-08 | 2024-05-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2021-11-24 | 2021-09-30 | -0.18 | -0.21 | -0.03 | 16 |
Know Oramed Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oramed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oramed Pharmaceuticals backward and forwards among themselves. Oramed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Oramed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Squarepoint Ops Llc | 2024-06-30 | 81.8 K | State Street Corp | 2024-06-30 | 59.3 K | Jane Street Group Llc | 2024-06-30 | 56.1 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 48.8 K | Lpl Financial Corp | 2024-09-30 | 38.7 K | Pnc Financial Services Group Inc | 2024-09-30 | 26.2 K | Wells Fargo & Co | 2024-06-30 | 25.6 K | Geode Capital Management, Llc | 2024-09-30 | 25.5 K | Xtx Topco Ltd | 2024-09-30 | 24.7 K | Bml Capital Management Llc | 2024-09-30 | 2.2 M | Murchinson Ltd. | 2024-06-30 | 1.7 M |
Oramed Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 94.58 M.Market Cap |
|
Oramed Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.23) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.22) | (0.24) |
Determining Oramed Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Oramed Pharmaceuticals is a good buy. For example, gross profit margin measures Oramed Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oramed Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Oramed Pharmaceuticals' management efficiency
Oramed Pharmaceuticals has return on total asset (ROA) of (0.0412) % which means that it has lost $0.0412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0289 %, meaning that it created $0.0289 on every $100 dollars invested by stockholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/27/2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Oramed Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 11/27/2024, Liabilities And Stockholders Equity is likely to grow to about 195.2 M, while Non Current Liabilities Total is likely to drop slightly above 4.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.49 | 3.66 | |
| Tangible Book Value Per Share | 3.49 | 3.66 | |
| Enterprise Value Over EBITDA | (10.46) | (10.98) | |
| Price Book Value Ratio | 2.78 | 2.92 | |
| Enterprise Value Multiple | (10.46) | (10.98) | |
| Price Fair Value | 2.78 | 2.92 | |
| Enterprise Value | 386.6 M | 405.9 M |
Oramed Pharmaceuticals has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 1.77 |
Basic technical analysis of Oramed Stock
As of the 27th of November, Oramed Pharmaceuticals holds the Coefficient Of Variation of (4,226), risk adjusted performance of (0.01), and Variance of 5.4. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them.Oramed Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oramed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oramed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oramed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oramed Pharmaceuticals' Outstanding Corporate Bonds
Oramed Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oramed Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oramed bonds can be classified according to their maturity, which is the date when Oramed Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US68404LAA08 Corp BondUS68404LAA08 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Oramed Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Oramed Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 1.76 | |||
| Coefficient Of Variation | (4,226) | |||
| Standard Deviation | 2.32 | |||
| Variance | 5.4 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.43) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 11.99 | |||
| Value At Risk | (3.33) | |||
| Potential Upside | 3.4 | |||
| Skewness | 0.1537 | |||
| Kurtosis | 0.7257 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 1.76 | |||
| Coefficient Of Variation | (4,226) | |||
| Standard Deviation | 2.32 | |||
| Variance | 5.4 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.43) | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 11.99 | |||
| Value At Risk | (3.33) | |||
| Potential Upside | 3.4 | |||
| Skewness | 0.1537 | |||
| Kurtosis | 0.7257 |
Consider Oramed Pharmaceuticals' intraday indicators
Oramed Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oramed Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 9161.84 | |||
| Daily Balance Of Power | 0.1538 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 2.37 | |||
| Day Typical Price | 2.37 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.02 |
Oramed Pharmaceuticals Corporate Filings
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 16th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Oramed Stock media impact
Far too much social signal, news, headlines, and media speculation about Oramed Pharmaceuticals that are available to investors today. That information is available publicly through Oramed media outlets and privately through word of mouth or via Oramed internal channels. However, regardless of the origin, that massive amount of Oramed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Oramed Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Oramed Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Oramed Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Oramed Pharmaceuticals alpha.
Oramed Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Oramed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Oramed Pharmaceuticals Corporate Executives
Elected by the shareholders, the Oramed Pharmaceuticals' board of directors comprises two types of representatives: Oramed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oramed. The board's role is to monitor Oramed Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oramed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oramed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Avraham Gabay | Treasurer CFO | Profile | |
| Joshua Hexter | COO and VP of Bus. Devel. | Profile |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.